GRM2 modulators have risen in interest, given that allosteric modulators of G-protein-coupled receptors (GPCRs) appear to provide a new strategy to develop novel treatments in neurodegenerative diseases in general and PD in particular [43]. This evidence concerns the gene GRM2 and neurodegenerative disease.